Division of Bristol-Myers Squibb Co.
Latest From ZymoGenetics Inc.
The pharma will consolidate some operations in New Jersey, it won’t renew the lease on a Seattle site acquired with ZymoGenetics deal and intends to close an R&D site in Connecticut as part of a cost-control plan outlined in October.
Douglas Williams turned heads in July when Biogen revealed that its executive vice president leading research and development was leaving to found a biotechnology startup, and now Williams has emerged from the fundraising process as the president and CEO of Codiak BioSciences with venture capital to develop exosomes-based therapeutics and diagnostics.
Before they began their summer vacations, three biotechnology companies raised $62m in venture capital financing and three drug developers grossed $232m in initial public offerings.
Novo Nordisk is dropping all its R&D activities into inflammatory disorders following the discontinuation of its lead anti-inflammatory product, anti-IL-20 for the treatment of rheumatoid arthritis, which it announced last month.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Bristol-Myers Squibb Co.
- Senior Management
Heather L Franklin, SVP, Bus. Dev.
Eleanor L Ramos, MD, SVP, CMO
Dennis M Miller, PhD, SVP, Research & Preclinical Dev.
- Contact Info
Phone: (206) 442-6600
1201 Eastlake Ave. East
Seattle, WA 98102-3702
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.